Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiselimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 11/20 | 1.00 |
| ▸ | S1PR3 known ✓ | Q99500 | 7/20 | 0.56 |
| ▸ | S1PR4 known ✓ | O95977 | 5/20 | 0.56 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 0.56 |
| ▸ | S1PR2 known ✓ | O95136 | 3/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.56 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.56 |
| ▸ | GPR183 | P32249 | 1/20 | 0.56 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiselimod SCHEMBL2463680 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL12336974 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL2468253 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2462139 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Amiselimod SCHEMBL30029360 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Amiselimod SCHEMBL2463915 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2465803 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL12336900 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2464567 | 0.94 | S1PR1 (0.89) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL12337616 | 0.94 | S1PR1 (0.89) | S1PR1S1PR3TNNC1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119405638-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2025-02-11 | — | — | CN | claimed |
| CN-118662488-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | claimed |
| CN-114980874-B | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2024-08-13 | — | — | CN | claimed |
| CN-115279355-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2022-11-01 | — | — | CN | claimed |
| CN-114980874-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2022-08-30 | — | — | CN | claimed |
| EP-4637819-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | Prometheus Biosciences, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250228850-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | IDORSIA PHARMACEUTICALS LTD. (CH) | 2025-07-17 | — | — | US | disclosed |
| US-20250170119-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025083549-A1 | METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2025-04-24 | — | — | WO | disclosed |
| CN-119405638-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-119405638-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-20250032474-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2025-01-30 | — | — | US | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| CN-115279355-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2022-11-01 | — | — | CN | disclosed |
| CN-115279355-A | Pharmaceutical composition | 田边三菱制药株式会社 | 2022-11-01 | — | — | CN | disclosed |
| EP-4051250-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | Idorsia Pharmaceuticals Ltd (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114980874-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-114980874-A | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | 田边三菱制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-114599363-A | Combinations of CXCR7 antagonists with S1P1 receptor modulators | 爱杜西亚药品有限公司 | 2022-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170119-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
| US-20250228850-A1 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | CXCR1, CXCR5, CXCL12 | S1PR1 5/4885S1PR3 12/4885S1PR4 16/4885 |
| US-20250032474-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.